ETNB
89bio, Inc.
Industry
Biotechnology
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Loading...
Open
8.85
Mkt cap
842M
Volume
1.4M
High
8.85
P/E Ratio
-2.68
52-wk high
16.63
Low
7.85
Div yield
N/A
52-wk low
7.00

Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 12:09 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.